The Genetics of BSVD4: COL4A1 and the Founder Mutation

While many genetic conditions are caused by a small “misspelling” in the DNA, Brain Small Vessel Disease 4 (BSVD4) is unique. It is caused by a structural change—a piece of mobile DNA that has inserted itself into the COL4A1 gene ^[1]. Understanding the specifics of this mutation helps explain why this condition behaves differently from other forms of cerebral small vessel disease (cSVD).

The Mutation: The AluYa5 “Jumping Gene”

The specific cause of BSVD4 is an AluYa5 insertion ^[1]. Alu elements are segments of DNA known as “jumping genes” or retrotransposons that can copy and paste themselves into different locations in our genome ^[1].

In BSVD4, this element has landed in a regulatory part of the COL4A1 gene called the 3′ untranslated region (3′UTR) ^[1]. Unlike most mutations that cause a gene to stop working, this insertion acts like a “stuck throttle” ^[1]:

• Upregulation: The insertion interferes with how the gene is “switched off.” This is thought to lead the body to produce approximately 10 times the normal amount of mRNA (the gene’s instructions) and nearly 3 times the normal amount of collagen type IV protein, based on experimental laboratory studies ^[1].
• Vessel Weakening: This massive overabundance of collagen protein disrupts the delicate balance of the basement membrane (the scaffolding) surrounding small blood vessels, which may make them prone to injury and leakage ^[1][2].

The Brittany Founder Effect

Researchers have discovered that some people diagnosed with this specific AluYa5 insertion are part of a larger genetic family tree. This is known as a founder effect ^[3].

• Geographic Origins: A specific study of 10 families with this mutation found that eight of them originated from the Brittany region of France ^[3].
• The Common Ancestor: Genetic analysis (specifically haplotype analysis) suggests that these individuals inherited the mutation from a common ancestor who was likely born around 1735 ^[3].
• Spread: Over the centuries, this mutation has been passed down through generations. However, this reported founder effect does not mean that every carrier worldwide descends from this person, nor is ancestry a requirement for diagnosis ^[3].

Patterns of Inheritance

BSVD4 follows an autosomal dominant inheritance pattern ^[4]. This means:

• 50% Chance: If one parent has the mutation, there is a 50% chance they will pass it on to each child, regardless of the child’s biological sex ^[4]. Note that inheriting the variant is not the same as inheriting a specific clinical outcome.
• Radiologic Penetrance: In one specific cohort study of the AluYa5 insertion, researchers found it had high “radiologic penetrance,” meaning about 89% of carriers eventually showed signs of the disease on a brain MRI, such as small lesions in the pons ^[1]. However, MRI penetrance is different from symptomatic disease; having an MRI finding does not guarantee an equivalent risk of clinical stroke.
• Variable Expression: Even within the same family, the age when symptoms start and how severe they are can vary significantly (variable expressivity) ^[4]. Some family members may only have “silent” findings on an MRI, while others may experience symptoms in their 30s or 40s ^[5][1].

Distinguishing BSVD4 from Other Conditions

BSVD4 is one of several genetic conditions that affect the small blood vessels of the brain. It is important to distinguish it from others because the management and risks may differ.

While these conditions all cause cerebral small vessel disease, BSVD4 is specifically defined by the AluYa5 genetic signature and its link to the historical lineage ^[3]. Knowing this specific genetic identity allows your doctors to provide more tailored screening for other organs, such as the eyes and kidneys, which are also part of the COL4A1 spectrum ^[10].